See more : Douzone Bizon Co., Ltd. (012510.KS) Income Statement Analysis – Financial Results
Complete financial analysis of ACADIA Pharmaceuticals Inc. (ACAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACADIA Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Audinate Group Limited (AUDGF) Income Statement Analysis – Financial Results
- Crowell Development Corp. (2528.TW) Income Statement Analysis – Financial Results
- Nishio Rent All Co., Ltd. (9699.T) Income Statement Analysis – Financial Results
- SES AI Corporation (SES) Income Statement Analysis – Financial Results
- Pharmagest Interactive SA (PHA.PA) Income Statement Analysis – Financial Results
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726.44M | 517.24M | 484.15M | 441.76M | 339.08M | 223.81M | 124.90M | 17.33M | 61.00K | 120.00K | 1.15M | 4.91M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Cost of Revenue | 45.73M | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M | 13.06M | 4.41M | 76.37M | 60.60M | 26.72M | 18.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 680.71M | 507.07M | 465.00M | 421.21M | 319.48M | 205.48M | 111.84M | 12.93M | -76.31M | -60.48M | -25.58M | -13.89M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Gross Profit Ratio | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% | 74.58% | -125,095.08% | -50,401.67% | -2,233.80% | -283.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 351.62M | 361.58M | 239.42M | 319.13M | 240.39M | 187.16M | 149.19M | 99.28M | 73.87M | 60.60M | 26.72M | 18.79M | 17.31M | 20.58M | 41.59M | 56.75M | 57.94M | 49.40M | 30.85M | 23.45M | 16.94M | 14.92M | 13.09M | 9.73M |
| General & Administrative | 393.07M | 363.59M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Selling & Marketing | 9.40M | 5.50M | 41.80M | 51.10M | 38.30M | 39.80M | 15.60M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 402.47M | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Other Expenses | 0.00 | 3.54M | 2.33M | -997.00K | 997.00K | -1.84M | 3.98M | 1.33M | 2.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.56M | 7.53M | 2.36M | 0.00 | 0.00 | 2.15M | 2.85M |
| Operating Expenses | 754.09M | 730.67M | 635.44M | 707.79M | 566.02M | 452.92M | 404.25M | 285.74M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Cost & Expenses | 799.82M | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M | 417.31M | 290.15M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Interest Income | 17.23M | 6.61M | 591.00K | 6.61M | 11.17M | 5.35M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 82.00K | 409.00K | 2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 86.00K | 181.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 2.03M | 3.34M | 2.93M | 2.77M | 3.01M | 2.71M | 1.83M | 647.00K | 206.00K | 79.00K | 109.00K | 285.00K | 607.00K | 1.11M | 1.04M | 768.00K | -146.00K | 1.03M | 1.31M | 1.34M | 1.40M | 0.00 | 0.00 |
| EBITDA | -67.83M | -221.57M | -167.10M | -286.59M | -243.78M | -244.44M | -289.70M | -270.99M | -163.47M | -93.02M | -38.22M | -20.78M | -22.48M | 15.70M | -44.36M | -66.98M | -62.65M | -49.05M | -32.93M | -24.18M | -12.40M | -11.22M | -15.28M | -11.27M |
| EBITDA Ratio | -9.34% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,337.82% | -425.64% | -1,091.78% | 37.26% | -693.19% | -4,212.45% | -819.14% | -646.92% | -317.45% | -538.40% | -168.01% | -178.84% | -411.39% | -261.34% |
| Operating Income | -73.38M | -223.60M | -170.44M | -286.59M | -246.55M | -247.44M | -292.41M | -272.82M | -164.61M | -93.23M | -38.30M | -20.89M | -22.85M | 15.09M | -45.47M | -66.98M | -62.65M | -49.05M | -35.81M | -26.10M | -13.74M | -12.63M | -15.28M | -11.27M |
| Operating Income Ratio | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,344.72% | -425.64% | -1,105.56% | 35.82% | -710.55% | -4,212.45% | -829.31% | -603.15% | -326.81% | -566.76% | -186.22% | -201.19% | -411.39% | -261.34% |
| Total Other Income/Expenses | 22.34M | 10.15M | 2.92M | 5.61M | 12.16M | 3.51M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 45.00K | 323.00K | 2.73M | 6.26M | 3.96M | -4.55M | 178.20K | 0.00 | 0.00 | 15.28M | 11.27M |
| Income Before Tax | -51.04M | -213.44M | -167.52M | -280.97M | -234.38M | -243.94M | -288.28M | -270.05M | -164.11M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -7.03% | -41.27% | -34.60% | -63.60% | -69.12% | -108.99% | -230.81% | -1,558.20% | -269,037.70% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 10.25M | 2.53M | 351.00K | 611.00K | 876.00K | 1.26M | 1.12M | 1.34M | 330.00K | -206.00K | 0.00 | -109.00K | 0.00 | 0.00 | 0.00 | -1.04M | 0.00 | -3.86M | -200.00 | -200.00 | 352.60K | 242.30K | 14.41M | 10.19M |
| Net Income | -61.29M | -215.98M | -167.87M | -281.58M | -235.26M | -245.19M | -289.40M | -271.39M | -164.44M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | -14.09M | -12.87M | -14.41M | -10.19M |
| Net Income Ratio | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1,565.94% | -269,578.69% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | -191.00% | -205.05% | -387.88% | -236.41% |
| EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -9.66 | -8.86 | -11.93 | -9.53 |
| EPS Diluted | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -1.24 | -8.86 | -11.93 | -9.53 |
| Weighted Avg Shares Out | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 54.87M | 52.18M | 38.59M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 1.46M | 1.45M | 1.21M | 1.07M |
| Weighted Avg Shares Out (Dil) | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 11.37M | 1.45M | 1.21M | 1.07M |
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, pipeline setbacks, along with stiff competition and dependency on Nuplazid sales, remain a woe.
Acadia Pharmaceuticals: Back In The Buy Zone
Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to Nuplazid Phase 3 trial failure for schizophrenia. Despite setbacks, Acadia has strong financials with $470.5 million in cash and investments, and is trading at two times...
Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS...
New Millie Report Finds Hybrid Maternal Healthcare Model Improve Deliveries, Patient Engagement and Cost Savings
BERKELEY, Calif.--(BUSINESS WIRE)--Millie, a modern maternity clinic, today revealed promising maternal health outcomes from the first cohort of more than 150 births from its hybrid model that combines midwifery-led care, doulas, and OB-GYN support with technology to provide more complete,...
Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments
ACADIA Pharmaceuticals is a biopharmaceutical company specializing in CNS disorder treatments, with two successful FDA-approved commercial products, Nuplazid and Daybue. Nuplazid, indicated for Parkinson's disease psychosis, generates over $300 million in yearly cash flow, while Daybue, approved for Rett syndrome,...
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and...
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of Magnolia's Guide to Adventuring, a new, 10-part, documentary video series by award-winning TV producer, AJ Tesler, and his wife, Jenny Tesler, featuring their 13-year-old daughter, Magnolia, who lives...
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 1:30 p.m. Eastern Time in New York, NY 2024 RBC...
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Source: https://incomestatements.info
Category: Stock Reports